Investigation on the Anti-Cancer Effects of HER2-Targeted CAR-T Cells Engineered Using the <i>PiggyBac</i> Transposon System.

ABSTRACT:

Background

Chimeric antigen receptor T (CAR-T) cell therapies have demonstrated significant clinical efficacy in hematological malignancies. However, their application to solid tumors remains substantially limited by multiple challenges, including the risk of off-target effects. Hence, optimizing CAR-T cells for stronger antigen binding is essential.

Methods

In this study, we employed a classical anti-human endothelial growth factor receptor 2 (HER2) single-chain variable fragment (scFv) derived from trastuzumab, alongside an anti-HER2-13 scFv identified from a combinatorial cellular CAR library, for the construction of a third-generation CAR-T cell. Meanwhile, the phenotypes and both in vitro and in vivo functions of CAR-T cells transduced with the two scFvs v

SUBMITTER: Li TT 

PROVIDER: S-EPMC12573187 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature